Securities class-action lawsuits targeting life sciences companies are highly defensible and are often dismissed by courts. But effective defense and insurance coverage requires coordination and communication from the start, panelists on a recent Lockton webcast said.
While litigation against life sciences companies are common, their outcomes often hinge on how well companies manage early-stage disclosures, investor expectations, and insurance strategy. The life sciences sector carries unique risks tied to clinical development cycles, regulatory approvals, and market sensitivity to trial results.
Panelists on Lockton’s webcast described a relatively predictable pattern in securities class-action filings against life sciences companies. Lawsuits frequently follow negative clinical trial outcomes, regulatory setbacks, or unexpected safety concerns, all of which can trigger sharp stock price declines.
These claims often allege that companies misled investors about the likelihood of success in drug development pipelines or failed to adequately disclose risks tied to trials and approvals. However, despite the frequency of such filings, courts regularly dismiss cases when plaintiffs fail to meet the high bar required to prove intent or material misrepresentation.
A key challenge for life sciences companies and senior executives: balancing transparency with scientific uncertainty. Drug development is iterative and unpredictable, yet public companies must communicate progress to investors in a way that is both accurate and compliant. Even well-intentioned disclosures can become the subject of litigation, particularly when forward-looking statements about trial timelines, endpoints, or regulatory pathways do not materialize as expected.
This unique feature of the industry means disclosures are often scrutinized with hindsight bias, with plaintiffs pointing to negative outcomes as evidence that earlier statements were misleading, even if those outcomes were not reasonably foreseeable at the time.
Given these risks, life sciences companies must align legal, executive, and insurance stakeholders early, well before a claim arises. Directors and officers liability (D&O) insurance plays a central role in managing financial exposure, but its effectiveness depends on timely notification, clear communication, and coordination with insurers.
Breakdowns in communication — either internally or with carriers — can complicate coverage and claims handling. That’s why early engagement with brokers and insurers can help ensure that defense strategies are supported from the outset and that coverage issues are minimized.
“Your broker is the point guard in a securities class action,” said Doug Greene, leader of BakerHostetler’s Securities and Governance Litigation team. “The broker is the bridge to the carriers and a bridge to the company and, ultimately, the company’s defense counsel in the case.”
Watch a replay (opens a new window) of the webcast for more insights.